1315495-82-9Relevant articles and documents
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1
Hurley, Christopher A.,Blair, Wade S.,Bull, Richard J.,Chang, Christine,Crackett, Peter H.,Deshmukh, Gauri,Dyke, Hazel J.,Fong, Rina,Ghilardi, Nico,Gibbons, Paul,Hewitt, Peter R.,Johnson, Adam,Johnson, Tony,Kenny, Jane R.,Kohli, Pawan Bir,Kulagowski, Janusz J.,Liimatta, Marya,Lupardus, Patrick J.,Maxey, Robert J.,Mendonca, Rohan,Narukulla, Raman,Pulk, Rebecca,Ubhayakar, Savita,Van Abbema, Anne,Ward, Stuart I.,Waszkowycz, Bohdan,Zak, Mark
, p. 3592 - 3598 (2013/07/25)
The identification of a novel fused triazolo-pyrrolopyridine scaffold, optimized derivatives of which display nanomolar inhibition of Janus kinase 1, is described. Prototypical example 3 demonstrated lower cell potency shift, better permeability in cells and higher oral exposure in rat than the corresponding, previously reported, imidazo-pyrrolopyridine analogue 2. Examples 6, 7 and 18 were subsequently identified from an optimization campaign and demonstrated modest selectivity over JAK2, moderate to good oral bioavailability in rat with overall pharmacokinetic profiles comparable to that reported for an approved pan-JAK inhibitor (tofacitinib).
